Dietary magnesium supplementation in cats with chronic kidney disease: A prospective double-blind randomized controlled trial

J Vet Intern Med. 2024 Jul-Aug;38(4):2180-2195. doi: 10.1111/jvim.17134. Epub 2024 Jul 1.

Abstract

Background: Plasma total magnesium concentration (tMg) is a prognostic indicator in cats with chronic kidney disease (CKD), shorter survival time being associated with hypomagnesemia. Whether this risk factor is modifiable with dietary magnesium supplementation remains unexplored.

Objectives: Evaluate effects of a magnesium-enriched phosphate-restricted diet (PRD) on CKD-mineral bone disorder (CKD-MBD) variables.

Animals: Sixty euthyroid client-owned cats with azotemic CKD, with 27 and 33 allocated to magnesium-enriched PRD or control PRD, respectively.

Methods: Prospective double-blind, parallel-group randomized trial. Cats with CKD, stabilized on a PRD, without hypermagnesemia (tMg >2.43 mg/dL) or hypercalcemia (plasma ionized calcium concentration, (iCa) >6 mg/dL), were recruited. Both intention-to-treat and per-protocol (eating ≥50% of study diet) analyses were performed; effects of dietary magnesium supplementation on clinicopathological variables were evaluated using linear mixed effects models.

Results: In the per-protocol analysis, tMg increased in cats consuming a magnesium-enriched PRD (β, 0.25 ± .07 mg/dL/month; P < .001). Five magnesium supplemented cats had tMg >2.92 mg/dL, but none experienced adverse effects. Rate of change in iCa differed between groups (P = .01), with decreasing and increasing trends observed in cats fed magnesium-enriched PRD and control PRD, respectively. Four control cats developed ionized hypercalcemia versus none in the magnesium supplemented group. Log-transformed plasma fibroblast growth factor-23 concentration (FGF23) increased significantly in controls (β, 0.14 ± .05 pg/mL/month; P = .01), but remained stable in the magnesium supplemented group (β, 0.05±.06 pg/mL/month; P =.37).

Conclusions and clinical importance: Magnesium-enriched PRD is a novel therapeutic strategy for managing feline CKD-MBD in cats, further stabilizing plasma FGF23 and preventing hypercalcemia.

Keywords: CKD‐MBD; anti‐calcemic; calcium; fibroblast growth factor‐23; hypercalcemia; magnesium oxide.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Animals
  • Calcium / blood
  • Cat Diseases* / diet therapy
  • Cat Diseases* / drug therapy
  • Cats
  • Diet / veterinary
  • Dietary Supplements*
  • Double-Blind Method
  • Female
  • Fibroblast Growth Factor-23
  • Magnesium* / administration & dosage
  • Magnesium* / blood
  • Magnesium* / therapeutic use
  • Male
  • Phosphates / blood
  • Prospective Studies
  • Renal Insufficiency, Chronic* / diet therapy
  • Renal Insufficiency, Chronic* / veterinary

Substances

  • Calcium
  • Fibroblast Growth Factor-23
  • Magnesium
  • Phosphates